Global Healthcare Contract Research Organization Market Report 2022: New Leveraging Technologies Are Accelerating Growth – Yahoo Finance
Global Healthcare Contract Research Organization Market
Dublin, Dec. 06, 2022 (GLOBE NEWSWIRE) — The “Global Healthcare Contract Research Organization Market (2022-2027) by Type, Service, End-Use, and Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis” report has been added to ResearchAndMarkets.com’s offering.
The Global Healthcare Contract Research Organization Market is estimated to be USD 49.37 Bn in 2022 and is expected to reach USD 80.86 Bn by 2027, growing at a CAGR of 10.37%.
Market Dynamics
Drivers
Rising Penchant for Outsourcing Activities
Growing Investments in Research and Development Activities Such as Regenerative Medicine
Patient Cliff
Restraints
Stringent Government Regulations
Opportunities
Emerging Demand from the Biosimilars and Biologics Sector
increasing Need Among Specialized Testing Services
Challenges
Quality Issues of Healthcare CRO Services
Market Segmentations
The Global Healthcare Contract Research Organization Market is segmented based on Type, Service, End-Use, and Geography.
By Type, the market is classified into Clinical Diagnostics, Drug Discovery, and Pre-Clinical.
By Service, the market is classified into Project Management/Clinical Supply Management, Data Management, Regulatory/Medical Affairs, Medical Writing, Clinical Monitoring, Quality Management/ Assurance, Bio-statistics, Investigator Payments, Laboratory, Patient and Site Recruitment, Technology Services, and Other Services.
By End-Use, the market is classified into Pharmaceutical & Biopharmaceutical Companies, Medical Device Companies, and Academic Institutes.
By Geography, the market is classified into Americas, Europe, Middle-East & Africa and Asia-Pacific.
Competitive Quadrant
The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.
Ansoff Analysis
The report presents a detailed Ansoff matrix analysis for the Global Healthcare Contract Research Organization Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.
The analyst analyses the Global Healthcare Contract Research Organization Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
Based on the SWOT analysis conducted on the industry and industry players, the analyst has devised suitable strategies for market growth.
Why buy this report?
The report offers a comprehensive evaluation of the Global Healthcare Contract Research Organization Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
The report includes an in-depth market analysis using Porter’s 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
The report also contains the competitive analysis using Positioning Quadrants, the analyst’s competitive positioning tool.
Report Highlights:
A complete analysis of the market, including parent industry
Important market dynamics and trends
Market segmentation
Historical, current, and projected size of the market based on value and volume
Market shares and strategies of key players
Recommendations to companies for strengthening their foothold in the market
Report Attribute
Details
No. of Pages
210
Forecast Period
2022 – 2027
Estimated Market Value (USD) in 2022
$49.37 Billion
Forecasted Market Value (USD) by 2027
$80.86 Billion
Compound Annual Growth Rate
10.3%
Regions Covered
Global
Key Topics Covered:
1 Report Description
2 Research Methodology
3 Executive Summary
4 Market Dynamics
5 Market Analysis
6 Global Healthcare Contract Research Organization Market, By Type
7 Global Healthcare Contract Research Organization Market, By Service
8 Global Healthcare Contract Research Organization Market, By End-Use
9 Americas’ Healthcare Contract Research Organization Market
10 Europe’s Healthcare Contract Research Organization Market
11 Middle East and Africa’s Healthcare Contract Research Organization Market
12 APAC’s Healthcare Contract Research Organization Market
13 Competitive Landscape
14 Company Profiles
15 Appendix
Companies Mentioned
Azelix LLC
BioAgile Therapeutics Pvt. Ltd.
Charles River Laboratories International, Inc.
Clinical Trial Service B.V.
Clinipace, Inc.
Firma Clinical Research, LLC
Frontage Laboratories, Inc.
Geneticist Inc.
IQVIA Inc.
Labcorp
Linical Americas
Medpace Holdings, Inc.
Novotech Pty. Ltd.
Parexel International Corp.
PEPGRA Healthcare Pvt. Ltd.
PPD Inc.
PSI CRO Ag
SGS SA
Syneos Health
WuXi AppTec
For more information about this report visit https://www.researchandmarkets.com/r/xgy8uq
Attachment
Global Healthcare Contract Research Organization Market
On a bad day for most stocks, shares of electric-vehicle-related ChargePoint Holdings (NYSE: CHPT) and QuantumScape (NYSE: QS), and hydrogen fuel cell maker Plug Power (NASDAQ: PLUG) are down between 6% and 8%. There isn't any big news out from — or about — any of these three companies today that is the specific cause for any of their share-price declines. The most recent news is from ChargePoint, the EV charging station company, which reported third-quarter results on Dec. 1, with a 93% increase in revenue, but continues to report big losses.
Should investors prepare for a winter full of persistent headwinds? Inflation remains high, rising interest rates are putting a squeeze on capital as well as making consumer credit more expensive, and both the China COVID lockdowns and the Russian war in Ukraine continue to crimp global supply chains. But even though the markets are facing serious headwinds, not every stock is going to react by falling. According to the analysts at Wall Street giant Deutsche Bank, two interesting stocks are like
Shares of many of America's largest banks are tumbling again on Tuesday after a period of outperformance that saw Goldman Sachs Group GS claw back practically all of its losses year-to-date.
General Electric, whose spinoff of its health care and energy companies will leave Evendale-based GE Aerospace as the sole company, bought out every single print add in the New York Times for the first time in the newspaper's history.
Textron stock soared Tuesday after the defense company won a contract worth up to $80 billion to build a new helicopter for the Army. The Army is turning to Textron (ticker: TXT) subsidiary Bell Helicopter for a new long-range assault helicopter—the Bell V-280 Valor—that will replace the service’s 40-plus-year-old UH-60 Black Hawk. Textron beat a joint bid from Lockheed Martin (LMT) and Boeing (BA).
Even a dour outlook for the broader stock market couldn't outweigh good news for these companies.
Don’t get fooled into thinking the stock market’s recent positive action has legs. Morgan Stanley’s Chief U.S. Equity Strategist Mike Wilson thinks it’s time to take profits “before the Bear returns in earnest.” Wilson notes that his team’s tactical targets have been met and thinks the recent run-up has run its course. “Bear market rally runs into our original resistance levels–it's time to fade it,” says Wilson. With the “risk-reward of playing for more upside quite poor at this point,” Wilson
Binance CEO CZ is speaking out against SBF after FTX’s collapse and arguing he had nothing to do with his rival’s downfall.
The FTX-linked trading firm made a number of unorthodox investments in the months leading up to its stunning collapse.
Oppenheimer Senior Analyst Christopher Glynn joins Yahoo Finance Live to discuss upgrading GE to Outperform, the company’s stock performance, industrial stocks, and the outlook for GE’s health care spinoff.
While NIO and Li Auto (LI) hit monthly-record deliveries in November, XPeng (XPEV) sees a sharp fall in deliveries on a yearly basis.
The market rally has erased all the gains from Fed chief Jerome Powell's Nov. 30 speech. Apple and Exxon undercut key levels. Here's what to do now.
A broad cross-section of stocks tumbled again on Tuesday as market watchers focused on the Federal Reserve Bank's ongoing battle against inflation. Over the past several days, a couple of strong economic reports have increased concerns about the trajectory of an already overheated economy. With that as a backdrop, shares of Amazon (NASDAQ: AMZN) fell 2%, Alphabet (NASDAQ: GOOGL) (NASDAQ: GOOG) tumbled 2.4%, and Shopify (NYSE: SHOP) had slumped 4% as of 12:19 p.m. ET.
Recessions aren't fun to live through. But if you're prepared, they don't have to be painful for your portfolio, either.
Shares of Devon Energy (NYSE: DVN) fell 11.4% in November, according to data provided by S&P Global Market Intelligence. The primary factor weighing on the oil stock was its third-quarter report, where the company unveiled a lower total dividend payment. Devon Energy launched the oil industry's first fixed-plus-variable dividend framework in early 2021.
A strong jobs report these days runs counter to the Fed’s wishes. The line of thought is that if the job market is still too hot, the Fed won’t be keen on loosening its tight monetary policy in the ongoing efforts to tame inflation. And this is a scenario the market is keen to avoid after a series of 75 basis-point hikes this year. But J.P. Morgan Asset Management chief strategist David Kelly thinks the latest numbers flatter to deceive and believes the way the data is reported distorts the real
Blackstone Inc said redemptions from its $50 billion non-traded business development company reached its pre-set limit for the first time but investors were still allowed to cash out on their investments. This is the first time redemption requests had reached the pre-set limit of 5% since Blackstone launched the product in January last year. It also comes after Blackstone announced last Thursday that it would curb withdrawals from its $69 billion unlisted real estate income trust (REIT) following a surge in redemption requests.
The EV stock has been stuck in a range in recent weeks. That isn't going to change for a while, but if it does, the risk is skewed to the downside.
After a punishing 2022, it may be time to bet on bonds backed by the U.S. government, particularly if a recession hits, according to Truist Advisory Services.
When investors are in "risk-off" mode, unprofitable EV companies are often the first to be sold.